UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Educational Assessment and Inclusive Education: Paradoxes, Perspectives and Potentialities

1, 2023

Volltextzugriff (PDF)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

Journal of neurology, neurosurgery and psychiatry, 2020-06, Vol.91 (6), p.660-668

2020

Volltextzugriff (PDF)

Duration of post-vaccination immunity against yellow fever in adults

Vaccine, 2014-09, Vol.32 (39), p.4977-4984

Anon

2014

Volltextzugriff (PDF)

Checklist for patients with type 2 diabetes mellitus for remote consultation

Atención primaria, 2021-04, Vol.53 (4), p.101983-101983

2021

Volltextzugriff (PDF)

Avoidable adverse events in primary care. Retrospective cohort study to determine their frequency and severity

Atención primaria, 2020-12, Vol.52 (10), p.705

2020

Volltextzugriff (PDF)

Prospective randomised multicentre study to demonstrate the benefits of haemodialysis without acetate (with citrate): ABC-treat Study. Acute effect of citrate

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2019-07, Vol.39 (4), p.424-433

2019

Volltextzugriff (PDF)

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

Multiple sclerosis and related disorders, 2018-08, Vol.24, p.11-19

2018

Volltextzugriff (PDF)

Clinical and demographic aspects of secondary progressive multiple sclerosis in Argentina

Medicina, 2020, Vol.80 (6), p.606

2020

Volltextzugriff (PDF)

Cathode Ray Film Scanner

Review of scientific instruments, 1967-10, Vol.38 (10), p.1425-1430

1967

Volltextzugriff (PDF)

Economical Powering of a Large Multiplicity of Sputter-Ion Pumps

IEEE transactions on nuclear science, 1967, Vol.14 (3), p.836-837

1967

Volltextzugriff (PDF)

A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia

International clinical psychopharmacology, 2008-05, Vol.23 (3), p.138-149

2008

Volltextzugriff (PDF)

Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4105-4111

2003

Volltextzugriff (PDF)

Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery

British journal of anaesthesia : BJA, 2007-08, Vol.99 (2), p.202-211

2007

Volltextzugriff (PDF)

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4112-4119

2003

Volltextzugriff (PDF)

Aprepitant and Fosaprepitant: A 10‐Year Review of Efficacy and Safety

The oncologist (Dayton, Ohio), 2015-04, Vol.20 (4), p.450-458

2015

Volltextzugriff (PDF)

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists

European journal of cancer (1990), 2003-05, Vol.39 (8), p.1074-1080

2003

Volltextzugriff (PDF)

The role of surgery in Conn's syndrome -a case of refractory hypertension secondary to an aldosterone secreting adenoma

South African Journal of Surgery, 2021-09, Vol.59 (3)

2021

Volltextzugriff (PDF)

Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1759-1767

2001

Volltextzugriff (PDF)

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

Supportive care in cancer, 2010-09, Vol.18 (9), p.1171-1177

2010

Volltextzugriff (PDF)

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Journal of clinical oncology, 2011-04, Vol.29 (11), p.1495-1501

2011

Volltextzugriff (PDF)

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in latin america

Cancer, 2003-06, Vol.97 (12), p.3090-3098

2003

Volltextzugriff (PDF)

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

Supportive care in cancer, 2011-06, Vol.19 (6), p.807-813

2011

Volltextzugriff (PDF)

The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials

European journal of cancer (1990), 2004-02, Vol.40 (3), p.403-410

2004

Volltextzugriff (PDF)

Experimental design issues in choice-based conjoint applied to patient choice in healthcare

Journal of comparative effectiveness research, 2020-02, Vol.9 (2), p.141-147

2020

Volltextzugriff (PDF)

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

The New England journal of medicine, 1999-01, Vol.340 (3), p.190-195

1999

Volltextzugriff (PDF)

1 – 25 von 177

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(145)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Educational Assessment and Inclusive Education: Paradoxes, Perspectives and Potentialities

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

Duration of post-vaccination immunity against yellow fever in adults

Checklist for patients with type 2 diabetes mellitus for remote consultation

Avoidable adverse events in primary care. Retrospective cohort study to determine their frequency and severity

Prospective randomised multicentre study to demonstrate the benefits of haemodialysis without acetate (with citrate): ABC-treat Study. Acute effect of citrate

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

Clinical and demographic aspects of secondary progressive multiple sclerosis in Argentina

Cathode Ray Film Scanner

Economical Powering of a Large Multiplicity of Sputter-Ion Pumps

A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia

Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open abdominal surgery

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Aprepitant and Fosaprepitant: A 10‐Year Review of Efficacy and Safety

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists

The role of surgery in Conn's syndrome -a case of refractory hypertension secondary to an aldosterone secreting adenoma

Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in latin america

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials

Experimental design issues in choice-based conjoint applied to patient choice in healthcare

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

Suchergebnisse filtern